The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

[1] Gazdar AF(2017)Small-cell lung cancer: what we know, what we need to know and the path forward Nat Rev Cancer 17 725-737

[2] Bunn PA(2017)Unravelling the biology of SCLC: implications for therapy Nat Rev Clin Oncol 14 549-561

[3] Minna JD(2015)Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21 2244-2255

[4] Sabari JK(2018)First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer N Engl J Med 379 2220-2229

[5] Lok BH(2007)FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247-1252

[6] Laird JH(2010)Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors Expert Rev Anticancer Ther 10 997-1008

[7] Poirier JT(2015)Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review Ther Adv Hematol 6 202-208

[8] Rudin CM(2016)Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma P T 41 296-300

[9] Pietanza MC(2004)Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl] benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells Int J Cancer 110 301-308

[10] Byers LA(2004)The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol Cancer Ther 3 1397-1402

[1] Gazdar AF(2017)Small-cell lung cancer: what we know, what we need to know and the path forward Nat Rev Cancer 17 725-737

[2] Bunn PA(2017)Unravelling the biology of SCLC: implications for therapy Nat Rev Clin Oncol 14 549-561

[3] Minna JD(2015)Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21 2244-2255

[4] Sabari JK(2018)First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer N Engl J Med 379 2220-2229

[5] Lok BH(2007)FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247-1252

[6] Laird JH(2010)Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors Expert Rev Anticancer Ther 10 997-1008

[7] Poirier JT(2015)Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review Ther Adv Hematol 6 202-208

[8] Rudin CM(2016)Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma P T 41 296-300

[9] Pietanza MC(2004)Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl] benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells Int J Cancer 110 301-308

[10] Byers LA(2004)The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol Cancer Ther 3 1397-1402